The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > CETP apoB100 mouse model

CETP apo B100 HFD mouse model

A diet-induced animal model with a “human-­like” lipoprotein profile to evaluate your compounds affecting both diabetes and dyslipidemia

key benefits

  • To test drugs affecting both diabetes and dyslipidemia in an obese, insulin resistant and dyslipidemic model.
  • A model specifically designed to perform the most predictive in vivo experiments: euglycemic hyperinsulinemic clamp, in vivo macrophage-to-­feces reverse cholesterol transport (RCT) and LDL/HDL kinetics.

pharmacological validation

  • Positive reference compounds: torcetrapib, metformin, sitagliptin

Fact sheet

CETP ApoB100 mouse high fat diet model

REFERENCES

Briand F. et al. ADA scientific sessions, 2011.